Physician profile
Imran M Shaikh
NPI 1699120535
$7,506.09
in general payments reported to CMS, 2019-2025
35 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.02 · 2021: $806 · 2022: $2,542 · 2023: $1,320 · 2024: $1,098 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,939 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,939.02 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,447.83 | 2022-2025 | Inspire |
| Harmony Biosciences LLC | $1,107.19 | 2021-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $810.19 | 2022-2025 | Xywav |
| Amgen INC. | $460.40 | 2021-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $352.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $308.86 | 2021-2025 | Farxiga, Breztri |
| Preventric Diagnostics, INC. | $297.76 | 2021 | |
| Lilly USA, LLC | $280.23 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Avadel Cns Pharmaceuticals, LLC | $180.10 | 2024-2025 | Lumryz |
| Bayer Healthcare Pharmaceuticals INC. | $135.60 | 2021-2025 | |
| Neurelis, INC. | $121.06 | 2021 | |
| Viiv Healthcare Company | $109.80 | 2021-2025 | Cabenuva, Apretude |
| Abbvie INC. | $109.54 | 2022-2024 | Dalvance |
| Novartis Pharmaceuticals Corporation | $103.69 | 2022-2025 | |
| Axsome Therapeutics, INC. | $79.04 | 2024-2025 | Sunosi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.71 | 2022-2023 | |
| Gilead Sciences, INC. | $73.67 | 2023 | Epclusa |
| Janssen Pharmaceuticals, INC | $57.31 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.25 | 2021-2024 | Spiriva Respimat |
| Paratek Pharmaceuticals, INC. | $37.67 | 2025 | Nuzyra |
| Astellas Pharma US INC | $37.21 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $29.63 | 2024-2025 | Arexvy, Shingrix |
| Chiesi USA, INC. | $29.02 | 2020 | |
| Almatica Pharma LLC | $28.06 | 2022 | |
| Welch Allyn | $24.38 | 2021 | |
| Exact Sciences Corporation | $24.19 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $22.05 | 2021 | |
| Itamar Medical INC | $20.43 | 2023 | Watchpatone |
| Fisher & Paykel Healthcare INC | $18.67 | 2022 | |
| Philips North America LLC | $15.41 | 2023 | |
| Shionogi INC | $15.10 | 2022 | |
| Daiichi Sankyo INC. | $14.83 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.73 | 2025 | Voquezna |
| Resmed Corp | $14.37 | 2024 | |
| Eisai INC. | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.